- Home
- VSTM vs TLSI Comparison
VSTM vs TLSI Comparison
Compare VSTM & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- TLSI
- Stock Information
- Founded
- VSTM 2010
- TLSI 2010
- Country
- VSTM United States
- TLSI United States
- Employees
- VSTM N/A
- TLSI N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- TLSI Medical Specialities
- Sector
- VSTM Health Care
- TLSI Health Care
- Exchange
- VSTM Nasdaq
- TLSI Nasdaq
- Market Cap
- VSTM 132.0M
- TLSI 124.9M
- IPO Year
- VSTM 2012
- TLSI N/A
- Fundamental
- Price
- VSTM $3.85
- TLSI $4.27
- Analyst Decision
- VSTM Strong Buy
- TLSI Strong Buy
- Analyst Count
- VSTM 8
- TLSI 5
- Target Price
- VSTM $14.57
- TLSI $12.10
- AVG Volume (30 Days)
- VSTM 950.0K
- TLSI 30.5K
- Earning Date
- VSTM 11-06-2024
- TLSI 11-14-2024
- Dividend Yield
- VSTM N/A
- TLSI N/A
- EPS Growth
- VSTM N/A
- TLSI N/A
- EPS
- VSTM N/A
- TLSI N/A
- Revenue
- VSTM $10,000,000.00
- TLSI $26,892,000.00
- Revenue This Year
- VSTM N/A
- TLSI $61.76
- Revenue Next Year
- VSTM $108.05
- TLSI $47.30
- P/E Ratio
- VSTM N/A
- TLSI N/A
- Revenue Growth
- VSTM N/A
- TLSI 67.92
- 52 Week Low
- VSTM $2.10
- TLSI $3.33
- 52 Week High
- VSTM $14.22
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- VSTM 54.40
- TLSI 51.18
- Support Level
- VSTM $3.71
- TLSI $3.74
- Resistance Level
- VSTM $4.29
- TLSI $4.30
- Average True Range (ATR)
- VSTM 0.33
- TLSI 0.34
- MACD
- VSTM -0.05
- TLSI 0.01
- Stochastic Oscillator
- VSTM 31.82
- TLSI 58.37
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.